Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Editas Medicine's 3-Year RORE % for the quarter that ended in Mar. 2026 was -13.66%.
The industry rank for Editas Medicine's 3-Year RORE % or its related term are showing as below:
EDIT's 3-Year RORE % is ranked worse than 52.28% of 1293
companies
in the Biotechnology industry
Industry Median: -11.55
vs EDIT: -13.66
Editas Medicine (NAS:EDIT) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Editas Medicine 3-Year RORE % Related Terms
Editas Medicine 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Editas Medicine's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EDIT vs SGMT, AUTL, FBRX: 3-Year RORE % Comparison
For the Biotechnology subindustry, Editas Medicine's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Editas Medicine 3-Year RORE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Editas Medicine's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Editas Medicine's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
Editas Medicine (EDIT) has a 3-Year RORE % of -13.66 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Editas Medicine and its competitors. According to the industry distribution chart, Editas Medicine ranks #676 out of 1293 companies in the Biotechnology industry, placing it in the top 52.3%.
Is Editas Medicine's 3-Year RORE % too high?
Editas Medicine's current 3-Year RORE % is -13.66. Based on the distribution chart, Editas Medicine ranks #676 out of 1293 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Editas Medicine has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Editas Medicine's 3-Year RORE % compare to SGMT and AUTL?
According to the Biotechnology industry distribution chart, Editas Medicine ranks #676 out of 1293 companies for 3-Year RORE %. This places Editas Medicine in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Editas Medicine and its competitors. Editas Medicine's current 3-Year RORE % is -13.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Editas Medicine stock overvalued right now?
Based on GuruFocus' analysis, Editas Medicine (EDIT) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.87, compared to a current price of $3.64 — trading 94.7% above its estimated fair value. The current 3-Year RORE % is -13.66. Editas Medicine's overall GF Score™ is 45/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Editas Medicine (EDIT), the current 3-Year RORE % is -13.66 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Editas Medicine (EDIT) Overvalued in 2026?
Based on GuruFocus' analysis, Editas Medicine stock appears to be overvalued.
The current stock price of $3.64 is trading 94.7% above its estimated GF Value™ of $1.87.
GuruFocus considers Editas Medicine to be Significantly Overvalued.
Key valuation signals for EDIT:
3-Year RORE %: -13.66
GF Value™: $1.87 vs. price of $3.64 (94.7% above fair value)
No single metric tells the full story. See the EDIT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
45GF Score
Get the complete analysis for EDIT
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EDIT has been successfully added to your 
